# Decision Room — case_03_operational_organizational

> _Read-only rendering of Step 9 verdict, Step 10 operative/theoretical, Step 11 summary._  
> _See `src/elif_v0_1/viewers/` for source; see [notes/elif_v1_viewer_audit_and_spec.md] for spec._

## Run header
| Field | Value |
|---|---|
| case_id | case_03_operational_organizational |
| condition | c |
| run_id | run_5e1d7230e857448999d22384511732b0 |
| procedure_version | v1.0 |
| offline_mode | False |
| started_at_iso | 2026-05-30T12:59:52Z |

## Step 9 — Verdict
| Field | Value |
|---|---|
| verdict | constrain |
| confidence | High on authorizing the A1–A5 roadmap as constrained; medium on gate-condition sufficiency and sequencing rigidity between A3 and A4 |

### verdict_detail

The Step 8 stage-gated roadmap (A1–A5) is authorized to proceed only under the following explicit constraints: (1) Sequential gate integrity — no stage may begin until its predecessor gate artifact is deposited in a version-controlled, publicly accessible repository and attested by the named reviewers; any deviation from this sequencing requires a documented exception approved by the independent ethics reviewer. (2) Actor taxonomy sufficiency — the A1 output must contain explicit, separately enumerated entries for all three actor expansions (population-as-commons, clinicians-as-distinct-class, community-governed federated configurations); a taxonomy that conflates any two of these entries fails the gate and must be revised before A2 begins. (3) Instrument provenance completeness — the A2 provenance map must achieve zero unexamined instruments with no exceptions; instruments flagged for AI-assisted validation lineage or industry funding within ten years must be either replaced or carry a mitigation plan bearing the independent ethics reviewer's dated signature. (4) Pre-registration enforceability — the A3 comparative protocol must be registered on a recognized platform with a public, retrievable URL before any historical case data is accessed; retrieval must be verified by at least one team member not involved in protocol drafting. (5) Long-horizon budgetary commitment — the A4 feasibility table must include formal budget attestation for at least one concurrent-eligible long-horizon component before A5 synthesis begins; informal or provisional allocations do not satisfy this gate. (6) Adversarial review binding force — the A5 adversarial session must produce a written record; any newly identified OOF-class blind spot not assigned to a named owner with a scheduled resolution date before downstream empirical data collection constitutes a gate failure requiring the session to be reconvened. The roadmap is not authorized as a bundled whole executed in parallel; it is authorized strictly as a sequentially gated program subject to the constraints enumerated above.

### Unresolved uncertainty sources

- Gate-condition sufficiency for A1: it is unresolved whether two domain-expert sign-offs (health-law and STS) are sufficient to validate the actor taxonomy against emergent governance configurations not yet represented in either discipline's literature, which would materially update whether the A1 gate should require a third reviewer from a community-governance or public-health-ethics background.
- Sequencing rigidity between A3 and A4: it is unresolved whether A4 long-horizon methodology design genuinely requires A3 comparative-protocol outputs as inputs for all components, or whether some long-horizon methods (e.g., simulation modeling) can be fully specified independently; resolution would materially update whether A4 should remain downstream of A3 or be partially parallelized.
- Measurement-instrument replacement feasibility for A2: it is unresolved whether clean-provenance alternatives exist for all flagged instruments in the planned H1–H4 measurement suite; if no clean alternative exists for a core construct, the mitigation-plan pathway may be the only option, and the adequacy of that pathway under the independent ethics reviewer's standards is not yet established.
- OOF-class blind-spot completeness after A5 adversarial review: it is unresolved whether the adversarial review structure (single reviewer tasked with OOF identification) is sufficient to surface blind spots that are structurally invisible to any single-discipline reviewer, which would materially update whether the A5 gate should require a multi-reviewer adversarial panel rather than a single designated reviewer.
- Temporal scope of 'ten-year' industry-funding flag in A2: it is unresolved whether ten years is the appropriate lookback window for instrument provenance assessment given variation in AI adoption timelines across health system contexts; a shorter or longer window could materially change which instruments are flagged and whether replacements are necessary.

## Step 10 — Operative vs Theoretical

### Operative (7 entries — what the verdict authorizes)

- Authorize and initiate Stage A1 activities immediately under the named constraints established in the step_9 verdict, without awaiting resolution of any theoretical questions.
- Apply the constrained A1–A5 roadmap as the operative governance framework; treat each stage gate as a mandatory hold point before proceeding to the next stage.
- Enforce the medium-confidence gate conditions as binding checkpoints at each A1–A5 transition, documenting gate pass/fail evidence before any stage advancement is approved.
- Treat sequencing between A3 and A4 as a constrained dependency requiring explicit re-evaluation at the A3 gate, given medium confidence on sequencing rigidity between those two stages.
- Record and surface any constraint violations or anomalies encountered during A1 execution as immediate escalation triggers under the governance verdict.
- Operate within the four hypotheses loaded from step_4 as the bounded hypothesis set; do not expand the hypothesis space operationally until a theoretical resolution warrants a governance re-review.
- Log all stage-gate outcomes against the five step_8 entries to maintain traceability between the operative roadmap and the prior stage-gated evidence base.

### Theoretical (5 entries — unresolved questions)

- Are the gate conditions defined at each A1–A5 transition individually sufficient to confirm or disconfirm the substantive question each stage is designed to test, or are they proxies that could pass while the underlying question remains open?
- Is the sequencing rigidity between A3 and A4 structurally necessary given the causal dependencies in the underlying scientific or structural model, or is it an artifact of the governance design that could be relaxed without epistemic loss?
- Which of the four step_4 hypotheses, if falsified by A1–A2 findings, would materially alter the design or ordering of A3–A5, and what evidence thresholds would constitute falsification?
- Do the five step_8 stage-gated entries collectively cover the full parameter space of the substantive question, or are there structural gaps that the A1–A5 roadmap will not expose even if all gates are passed?
- What is the minimum evidence quality required at each gate to distinguish genuine progress on the substantive question from procedural compliance alone, and has that threshold been formally specified?

### Absence log

Both strands are populated. Operative strand reflects actions authorized under the step_9 constrained verdict and roadmap. Theoretical strand reflects unresolved scientific and structural questions whose answers would materially update gate-condition sufficiency, sequencing rigidity, and hypothesis coverage — none of which are settled by the governance verdict itself.

## Step 11 — Run Summary
| Field | Value |
|---|---|
| final_verdict | constrain |
| step_count | 10 |
| llm_calls_used | 11 |
| post_refusal_closure | False |

## Run footer
| Field | Value |
|---|---|
| exit_code | 0 |
| completed_at_iso | 2026-05-30T13:03:03Z |
| memory_logger_entries_written | 14 |


---


_This rendering claims only what the artifact already claims. The Decision Room does not validate, score, or recommend; it renders. See `notes/elif_post_e2_divergence_audit.md` for substantive interpretation of any verdict shown above._